首页|中医药联合造血干细胞移植治疗恶性血液病的研究概况

中医药联合造血干细胞移植治疗恶性血液病的研究概况

扫码查看
原文链接
  • 万方数据
  • 维普
造血干细胞移植(HSCT)被认为是唯一有可能根治恶性血液病的方法,然而由于植入不良、移植相关并发症多、较高的复发率等不良事件,严重影响着患者的生存率和生命质量,现在西医并不能完全解决这些问题.总结归纳中医药干预HSCT的相关文献,认识到中医药在HSCT的多个环节起到协同增效、优势互补的作用.中医药联合HSCT可以调理移植前患者体质,提升造血干细胞动员采集质量,助力移植预处理并促进造血重建,同时还可以有效防治并发症和防止复发.因此,中医药联合HSCT具有十分广阔的发展前景.
Overview of Traditional Chinese Medicine Combined with Hematopoietic Stem Cell Transplantation in the Treatment of Malignant Haematological Diseases
Currently,hematopoietic stem cell transplantation(HSCT)is considered the only possible cure for malignant hematolog-ical diseases.However,poor implantation,many transplantation-related complications,and high relapse rates seriously affect the sur-vival rate and quality of life of patients,which are now not fully addressed by Western medicine.By summarizing the literature on traditional Chinese medicine(TCM)intervention in HSCT,it was recognized that TCM played a synergistic and complementary role in multiple aspects of HSCT.TCM combined with HSCT can regulate the patient's constitution before transplantation,improve the quality of hematopoietic stem cell mobilization and collection,facilitate transplantation pretreatment,and promote hematopoietic re-constitution.It can also effectively prevent complications and relapse.Therefore,TCM combined with HSCT has a very broad devel-opmental prospect.

Traditional Chinese medicineHaematopoietic stem cell transplantationMalignant hematological diseasesStem cell mobilizationTransplantation pretreatmentHematopoietic reconstitutionGraft-versus-host diseaseTransplantation-related com-plications

李宗宏、崔思远、殷学伟、吕纯懿、王敬毅、徐瑞荣

展开 >

山东中医药大学,济南,250355

山东中医药大学附属医院,济南,250014

中医药 造血干细胞移植 恶性血液病 干细胞动员 移植预处理 造血重建 移植物抗宿主病 移植并发症

国家自然科学基金面上项目国家自然科学基金面上项目山东省自然科学基金

8197454781903984ZR2020KH023

2024

10.3969/j.issn.1673-7202.2024.04.026

世界中医药
世界中医药学会联合会

世界中医药

CSTPCDCHSSCD北大核心
影响因子：1.266
ISSN：1673-7202
年,卷(期)：2024.19(4)
  • 52